Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3439539 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| LY3439539 | EXPERIMENTAL | LY3439539 administered intravenously (IV) |
| Name | Type | Description |
|---|---|---|
| LY3439539 | DRUG | Administered IV |
Inclusion Criteria: * Have gradual and progressive change in memory function reported by the participant or informant for 6 months or longer consistent with a diagnosis of dementia due to Alzheimer's disease * Have a Mini Mental Score Examination score of 16 to 24, inclusive * Meet plasma pTau crit...
Top 20 of 24 competitors
LY3439539 is an investigational small molecule being studied for the treatment of Alzheimer's Disease. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being evaluated in a clinical trial involving participants with Alzheimer's Disease.
LY3439539 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol LLY. The company is conducting a Phase 1 clinical trial to evaluate the safety and tolerability of LY3439539 in participants with Alzheimer's Disease.
LY3439539 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The ongoing Phase 1 trial is currently recruiting participants with Alzheimer's Disease to assess the drug's safety and other characteristics.
LY3439539 is being studied in one clinical trial with the identifier NCT07598370, titled "A Study of LY3439539 in Participants With Alzheimer's Disease." This Phase 1 trial is currently recruiting and aims to enroll 30 participants aged 50 years and older in the United States, Australia, New Zealand, and Singapore.
LY3439539 is not FDA approved. It is an investigational drug currently in Phase 1 clinical trials for Alzheimer's Disease. The drug is being studied to evaluate its safety and tolerability, and it has not yet completed the clinical development process required for regulatory approval.